David Larocca,
Vice President, Research and Development,
ReCyte Therapeutics
David Larocca has served as Vice President of Research and Development at ReCyte Therapeutics, Inc. since September 2013. He founded Mandala Biosciences, LLC in 2008, where he served as Chief Executive Officer. At Mandala, he managed a team focused on developing targeted nanoparticle probes for identifying, tracking and manufacturing purified therapeutic stem cells. Dr. Larocca previously held joint positions at Advanced Cell Technology (now Astellas) and the Sanford Burnham Medical Research Institute. He is author of over 40 scientific publications and inventor of 23 patents and patent applications in the fields of immunotherapy, gene therapy, and regenerative medicine. Dr. Larocca holds a Ph.D. in Molecular and Cellular Biology from the University of Southern California and a B.S. in Biology from Ithaca College. He did his post-doctoral training at Harvard University.
Overcoming Barriers to Therapeutic Exosome Production using Highly Scalable and Pure Embryonic Progenitor Cell Lines
Wednesday, 27 September 2017 at 15:00
Add to Calendar ▼2017-09-27 15:00:002017-09-27 16:00:00Europe/LondonOvercoming Barriers to Therapeutic Exosome Production using Highly Scalable and Pure Embryonic Progenitor Cell LinesExtracellular Vesicles 2017 in Cripps Court, Magdalene College, Cambridge, UKCripps Court, Magdalene College, Cambridge, UKSELECTBIOenquiries@selectbiosciences.com
Stem cell derived exosomes have shown promise in animal models as an alternative to stem cells for a wide range of regenerative medicine applications including ischemia, myocardial infarct, stroke, atherosclerosis, and wound healing. However, production of therapeutic exosomes for clinical use will require scalable, stable and relatively pure production cell lines. Commonly used adult stem cells such as MSCs typically suffer from poor proliferative capacity, donor variability, and population heterogeneity. These limitations may present a formidable barrier to translation of early preclinical studies to the clinic. To address the limitations of stem cell purity and scalability, we derived hundreds of clonally pure and highly scalable human embryonic progenitor cell lines from pluripotent stem cells. We are currently investigating their potential as a scalable source of therapeutic exosomes. Using angiogenic exosomes as a case-study, we identified 6 scalable embryonic progenitor cell lines with angiogenic activity in a HUVEC tube forming assay including endothelial, pericyte and smooth muscle cell lines. The embryonic endothelial cell line, 30-MV2-6, expanded to over 75 population doublings (pd) compared to 16pd for adult bone-marrow MSCs. Moreover, 30-MV2-6 exosomes had >50-fold higher levels of the angiogenic miR-126 and 6-fold higher angiogenic potency than MSC exosomes. The 30-MV2-6 exosome production was stable to at least 50pd and the potential to scale on a hollow fiber bioreactor was demonstrated. We have identified a variety of distinct cell types including endothelial, smooth muscle, cartilage, bone, fat and pericyte cell lines in our library of over 250 progenitor cell lines. Our data indicates the potential of this library to provide a richly diverse source of exosome production lines that can be mined for variety of therapeutic exosomes.
Add to Calendar ▼2017-09-27 15:00:002017-09-27 16:00:00Europe/LondonOvercoming Barriers to Therapeutic Exosome Production using Highly Scalable and Pure Embryonic Progenitor Cell LinesExtracellular Vesicles 2017 in Cripps Court, Magdalene College, Cambridge, UKCripps Court, Magdalene College, Cambridge, UKSELECTBIOenquiries@selectbiosciences.com
